R&D Trends

Malaysian Bio-XCell, Agila Biotech ink $34M Build-and-Lease Agreement

Wednesday, March 20, 2013 10:37 AM

Malaysian Bio-XCell and Agila Biotech signed a $34.4 million Build-and-Lease Agreement for the establishment of a customized biotech facility located in the Bio-XCell biotechnology park and ecosystem in Nusajaya, Malaysia.

More... »

Wilex, Nuclea Biotechnologies form partnership

Wednesday, March 20, 2013 10:08 AM

Pittsfield, Mass-based biomarker pioneer Nuclea Biotechnologies has formed a new long-term partnership with biopharmaceutical company Wilex, which could lead to more effective treatment management for women with metastatic breast cancer. The partnership aims to advance R&D of biomarkers, a vital component in the growing field of personalized medicine. 

More... »

Scripps Research, Takeda expand research collaboration

Wednesday, March 20, 2013 09:11 AM

The Scripps Research Institute (TSRI), an independent, not-for-profit organization focusing on research in the biomedical sciences, and Takeda Pharmaceutical, a research-based global pharmaceutical company, plan to expand their recent research collaboration to search for new drug targets for a variety of diseases.

More... »

New Alzheimer’s Association report reveals one in three seniors dies with dementia

Tuesday, March 19, 2013 03:32 PM

According to the Alzheimer's Association’s just released 2013 Alzheimer's Disease Facts and Figures report, one in three U.S. seniors dies with Alzheimer’s or another dementia.

More... »

U.K.’s Technology Strategy Board and Indian government sign program of co-operation

Tuesday, March 19, 2013 11:30 AM

The Technology Strategy Board (TSB) and the Indian government’s Department of Science and Technology have agreed to undertake a joint program to support innovative U.K. and Indian businesses working together on the commercialization of research in a range of key areas, including energy and healthcare. The ‘Program of Co-operation’ was signed at an international reception held at the InnovateUK conference in London.

More... »

Avitide secures Series A financing for novel affinity purification tech

Monday, March 18, 2013 11:17 AM

Avitide, a biotech company dedicated to the discovery and development of custom affinity purification solutions, announced the closing of their Series A financing. The Avitide technology is designed to discover and develop affinity purification products that will improve the fundamental timeframes and economics of commercial bioprocessing.

More... »

J&J opens London innovation center

Wednesday, March 13, 2013 02:36 PM

Johnson & Johnson has opened the Johnson & Johnson Innovation center in London, one of four regional hubs being established this year in the world's leading innovation hotspots. A part of Johnson & Johnson Innovation, the goal of the London innovation center is to accelerate the best early stage science in the world and advance the development of new healthcare solutions.

More... »

Celtic Therapeutics rebrands as Auven Therapeutics

Wednesday, March 13, 2013 01:39 PM

Celtic Therapeutics Management, a global private equity company focused on acquiring novel, life-saving and quality of life-enhancing products and accelerating the development of these products, has changed its name to Auven Therapeutics Management.

More... »

Orion, Gedeon Richter ink novel CNS R&D collaboration agreement

Wednesday, March 13, 2013 11:37 AM

Orion, a Finnish pharmaceutical company, and Gedeon Richter, a Hungarian pharmaceutical company, have entered into a comprehensive and long term collaboration agreement for the discovery and development of new chemical entities in the field of cognitive disorders.

More... »

Astellas, Ambit terminate collaboration on FLT3 kinase inhibitors

Wednesday, March 13, 2013 10:39 AM

Tokyo-based Astellas Pharma and San Diego-based Ambit Biosciences will end their collaboration for the joint development and commercialization of FMS-like tyrosine kinase-3 (FLT3) inhibitors, including quizartinib, effective September 3, 2013.

More... »